How do the various targeted therapy options like EGFR inhibitors, VEGF inhibitors, and BRAF inhibitors work? And...
According to the NCCN Guidelines for Colorectal Cancer, targeted therapy selection is primarily determined by specific biomarker testing of your tumor. Here's a breakdown:
- EGFR Inhibitors (like cetuximab and panitumumab):
- According to ASCO Guidelines, these work by blocking epidermal growth factor receptors that cancer cells use to grow
- IMPORTANT: These are only recommended for patients with RAS wild-type tumors (no KRAS/NRAS mutations)
- The American Cancer Society notes that EGFR inhibitors are typically used in combination with chemotherapy or as single agents in later lines of therapy
- VEGF Inhibitors (like bevacizumab):
- The National Cancer Institute explains these work by blocking blood vessel formation that feeds tumors
- According to NCCN Guidelines, these can be used regardless of tumor mutation status
- Can be combined with various chemotherapy regimens
- BRAF Inhibitors:
- NCCN Guidelines specify these are only for patients with BRAF V600E mutations (found in about 8-10% of colorectal cancers)
- Usually combined with EGFR inhibitors and sometimes chemotherapy
Key Determining Factors: According to current NCCN Guidelines, your specific targeted therapy options will be determined by:
- Molecular testing results (RAS, BRAF, MSI status)
- Location of your tumor (left vs right side of colon)
- Previous treatments and how you responded
- Overall health status
Always remember that treatment decisions should be made in consultation with your oncology team, as they can evaluate all these factors in the context of your specific situation.
Sources:
- NCCN Guidelines for Colorectal Cancer (2023)
- ASCO Clinical Practice Guidelines for Metastatic Colorectal Cancer
- American Cancer Society's Targeted Therapy for Colorectal Cancer Guide
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Colon Cancer — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 15, 2025. Informational only — not a substitute for your oncology team.
Question asked:
How do the various targeted therapy options like EGFR inhibitors, VEGF inhibitors, and BRAF inhibitors work? And what factors determine which targeted therapy would be most appropriate for my particular case?
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Colon Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for Colorectal Cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Colorectal Cancer
- How does antibody-drug conjugate (ADC) therapy work for Colorectal Cancer
- Anybody had experience with colon cancer trials? Targeted chemotherapy via inhibitors? I am very confused. As I...
- What does EGFR mutation mean for Colorectal Cancer treatment
- If my tumor is found to have a BRAF mutation, what specific treatment options would my oncologist recommend, and how...
- What are checkpoint inhibitors and how do they help with Colorectal Cancer
- What targeted therapies are available for Colorectal Cancer
- In more detail how the genetic markers (RAS, BRAF, MSI) you mentioned impact treatment options for colorectal cancer
- What is the role of PARP inhibitors in treating Colorectal Cancer